xtandi Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xtandi, and when can generic versions of Xtandi launch?
Xtandi is a drug marketed by Astellas and is included in two NDAs. There are four patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and eighty-four patent family members in thirty-four countries.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the enzalutamide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xtandi
A generic version of xtandi was approved as enzalutamide by ZYDUS PHARMS on September 26th, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for xtandi?
- What are the global sales for xtandi?
- What is Average Wholesale Price for xtandi?
Summary for xtandi
| International Patents: | 184 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 122 |
| Clinical Trials: | 155 |
| Patent Applications: | 1,748 |
| Drug Prices: | Drug price information for xtandi |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for xtandi |
| What excipients (inactive ingredients) are in xtandi? | xtandi excipients list |
| DailyMed Link: | xtandi at DailyMed |
Paragraph IV (Patent) Challenges for XTANDI
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| XTANDI | Tablets | enzalutamide | 40 mg and 80 mg | 213674 | 1 | 2021-03-31 |
| XTANDI | Capsules | enzalutamide | 40 mg | 203415 | 3 | 2016-08-31 |
US Patents and Regulatory Information for xtandi
xtandi is protected by eleven US patents and one FDA Regulatory Exclusivity.
Patents protecting xtandi
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Diarylhydantoin compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Treatment of hyperproliferative disorders with diarylhydantoin compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
Treatment of hyperproliferative disorders with diarylhydantoin compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
Treatment of hyperproliferative disorders with diarylhydantoin compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Treatment of hyperproliferative disorders with diarylhydantoin compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
Treatment of hyperproliferative disorders with diarylhydantoin compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE (BCR) AT HIGH RISK FOR METASTASIS
Treatment of hyperproliferative disorders with diarylhydantoin compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
Treatment of hyperproliferative disorders with diarylhydantoin compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
Treatment of hyperproliferative disorders with diarylhydantoin compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Treatment of hyperproliferative disorders with diarylhydantoin compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE (BCR) AT HIGH RISK FOR METASTASIS
FDA Regulatory Exclusivity protecting xtandi
TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | XTANDI | enzalutamide | TABLET;ORAL | 213674-002 | Aug 4, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Astellas | XTANDI | enzalutamide | TABLET;ORAL | 213674-002 | Aug 4, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Astellas | XTANDI | enzalutamide | CAPSULE;ORAL | 203415-001 | Aug 31, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Astellas | XTANDI | enzalutamide | TABLET;ORAL | 213674-001 | Aug 4, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Astellas | XTANDI | enzalutamide | TABLET;ORAL | 213674-001 | Aug 4, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Astellas | XTANDI | enzalutamide | TABLET;ORAL | 213674-001 | Aug 4, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Astellas | XTANDI | enzalutamide | TABLET;ORAL | 213674-001 | Aug 4, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for xtandi
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Astellas Pharma Europe B.V. | Xtandi | enzalutamide | EMEA/H/C/002639 Xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy. |
Authorised | no | no | no | 2013-06-21 | 2013-04-26 |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for xtandi
When does loss-of-exclusivity occur for xtandi?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 06248109
Patent: Diarylhydantoin compounds
Estimated Expiration: ⤷ Sign Up
Patent: 07245022
Patent: Diarylthiohydantoin compounds
Estimated Expiration: ⤷ Sign Up
Austria
Patent: 41571
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0610359
Patent: composto de diaril-hidantoìna, método de sintetização de compostos e método in vitro
Estimated Expiration: ⤷ Sign Up
Patent: 0709682
Patent: compostos de diariltioidantoÍna
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 08436
Patent: COMPOSES DIARYLHYDANTOINES (DIARYLHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 48139
Patent: COMPOSES DE DIARYLTHIOHYDANTOINE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES D'HYPERPROLIFERATION (DIARYL THIOHYDANTOIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1222922
Patent: Diarylhydantoin compounds
Estimated Expiration: ⤷ Sign Up
Patent: 1460467
Patent: Diarylthiohydantoin compounds
Estimated Expiration: ⤷ Sign Up
Patent: 2584712
Patent: Diarylhydantoin compounds
Estimated Expiration: ⤷ Sign Up
Patent: 2755318
Patent: Hyperproliferative disorders with diarylhydantoin compounds
Estimated Expiration: ⤷ Sign Up
Patent: 5037273
Patent: Diaryl hydantoin compound
Estimated Expiration: ⤷ Sign Up
Patent: 0003114
Patent: 二芳基乙内酰脲化合物 (Diaryl hydantoin compound)
Estimated Expiration: ⤷ Sign Up
Patent: 6003328
Patent: 二芳基乙内酰脲化合物 (Diaryl hydantoin compound)
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0120323
Estimated Expiration: ⤷ Sign Up
Patent: 0150437
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 12798
Estimated Expiration: ⤷ Sign Up
Patent: 16426
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 93196
Estimated Expiration: ⤷ Sign Up
Patent: 44085
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 93196
Patent: COMPOSE DIARYLHYDANTOINE (DIARYLHYDANTOIN COMPOUND)
Estimated Expiration: ⤷ Sign Up
Patent: 13187
Patent: COMPOSÉS DE DIARYLTHIOHYDANTOÏNE (DIARYLTHIOHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 39196
Patent: Composés de diarylthiohydantoïne destinés à être utilisés dans une méthode de traitement d'une maladie hyperproliférative (Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder)
Estimated Expiration: ⤷ Sign Up
Patent: 44085
Patent: Composés de diarylhydantoïne en tant qu'antagoniste du recepteur androgén pour le traitement du cancer (Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer)
Estimated Expiration: ⤷ Sign Up
Patent: 61871
Patent: Composés diarylhydantoines en tant qu'antagonistes du récepteur d'androgène pour le traitement du cancer (Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer)
Estimated Expiration: ⤷ Sign Up
Patent: 20706
Patent: DÉRIVÉS DE DIARYLTHIOHYDANTOÏNE UTILES POUR LE TRAITEMENT DE MALADIES HYPERPROLIFÉRATIVES (DIARYLTHIOHYDANTOIN COMPOUNDS USEFUL FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER)
Estimated Expiration: ⤷ Sign Up
Patent: 06162
Patent: COMPOSES DIARYLHYDANTOINES EN TANT QU'ANTAGONISTES DU RECEPTEUR D'ANDROGENE POUR LE TRAITEMENT DU CANCER (DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER)
Estimated Expiration: ⤷ Sign Up
Patent: 70721
Patent: COMPOSÉS DIARYLHYDANTOINES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR D'ANDROGÈNE POUR LE TRAITEMENT DU CANCER (DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 12856
Patent: DIARYLHYDANTOIN COMPOUND
Estimated Expiration: ⤷ Sign Up
Patent: 24612
Patent: 二芳基乙內酰硫脲化合物 (DIARYLTHIOHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 69321
Patent: 用於腫瘤治療作為雄激素受體拮抗劑的二芳基乙內酰脲化合物 (DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER)
Estimated Expiration: ⤷ Sign Up
Patent: 77691
Patent: 二芳基硫代乙內酰脲化合物 (DIARYLTHIOHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 17103
Patent: 二芳基乙內酰脲化合物 (DIARYLHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 300076
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 7328
Patent: N-מתיל-2-פלואורו-{4-[3-(4-ציאנו-3-טריפלואורומתילפניל)-5,5-דימתיל-4-אוקסו-2-תיאוקסו-אימידאזולידינ-1-איל]}בנזאמיד, תכשירים רוקחים המכילים אותו ושימוש בו להכנת תרופות (N-methyl-2-fluoro-{4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]}benzamide, pharmaceutical compositions comprising the same and uses thereof in the manufacture of medicaments)
Estimated Expiration: ⤷ Sign Up
Patent: 4438
Patent: תרכובות דיארילתיוהידנטואין, תכשירים רוקחיים המכילים אותן, שיטות לסינתוזן ושיטות אין-ויטרו להבאתן במגע עם תאי יונקים (Diarylthiohydantoin compounds, pharmaceutical compositions comprising them, methods for their synthesis and in vitro methods for contacting them with mammalian cells)
Estimated Expiration: ⤷ Sign Up
Patent: 8880
Patent: תרכובות של דיארילהידנתוין (Diarylhydantoin compounds)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 44737
Estimated Expiration: ⤷ Sign Up
Patent: 38753
Estimated Expiration: ⤷ Sign Up
Patent: 50780
Estimated Expiration: ⤷ Sign Up
Patent: 50217
Estimated Expiration: ⤷ Sign Up
Patent: 34670
Estimated Expiration: ⤷ Sign Up
Patent: 13535
Estimated Expiration: ⤷ Sign Up
Patent: 08540523
Estimated Expiration: ⤷ Sign Up
Patent: 09531449
Estimated Expiration: ⤷ Sign Up
Patent: 11068653
Patent: DIARYLHYDANTOIN COMPOUND
Estimated Expiration: ⤷ Sign Up
Patent: 12211190
Patent: DIARYLHYDANTOIN COMPOUND
Estimated Expiration: ⤷ Sign Up
Patent: 12236843
Patent: DIARYLHYDANTOIN COMPOUND
Estimated Expiration: ⤷ Sign Up
Patent: 13136642
Patent: DIARYLTHIOHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 15098497
Patent: ジアリールヒダントイン化合物 (DIARYLHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 15117244
Patent: ジアリールチオヒダントイン化合物 (DIARYLTHIOHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 16183200
Patent: ジアリールヒダントイン化合物 (DIARYLHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 17031223
Patent: ジアリールチオヒダントイン化合物 (DIARYLTHIOHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 17031224
Patent: ジアリールチオヒダントイン化合物 (DIARYLTHIOHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 18100292
Patent: ジアリールヒダントイン化合物 (DIARYLHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 19218352
Patent: ジアリールヒダントイン化合物 (DIARYLHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 21035970
Patent: ジアリールヒダントイン化合物 (DIARYLHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 22101657
Patent: ジアリールヒダントイン化合物
Estimated Expiration: ⤷ Sign Up
Patent: 23075313
Patent: ジアリールヒダントイン化合物
Estimated Expiration: ⤷ Sign Up
Luxembourg
Patent: 338
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 6924
Patent: COMPUESTOS DE DIARILHIDANTOINA. (DIARYLHYDANTOIN COMPOUNDS.)
Estimated Expiration: ⤷ Sign Up
Patent: 07014132
Patent: COMPUESTOS DE DIARILHIDANTOINA. (DIARYLHYDANTOIN COMPOUNDS.)
Estimated Expiration: ⤷ Sign Up
Patent: 08012492
Patent: COMPUESTOS DE DIARILTIOHIDANTOINA. (DIARYLTHIOHYDANTOIN COMPOUNDS.)
Estimated Expiration: ⤷ Sign Up
Patent: 19015200
Patent: COMPUESTOS DE DIARILHIDANTOINA. (DIARYLHYDANTOIN COMPOUNDS.)
Estimated Expiration: ⤷ Sign Up
Patent: 22009759
Patent: EL USO DE 1-(4-CIANO-3-TRIFLUOROMETIL-FENIL)-3-[7-(4-CIANO-3-TRIFL UOROMETIL-FENIL)-6-TIOXO-5-P-TOLILO-5,7-DIAZAESPIRO[3.4]OCT-8-ILI DENO]-TIOUREA. (DIARYLHYDANTOIN COMPOUNDS.)
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 992
Patent: JEDINJENJE DIARILHIDANTOINA (DIARYLHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 4223
Patent: Diarylhydantoin compounds for treating hormone refractory prostate cancer
Estimated Expiration: ⤷ Sign Up
Patent: 2374
Patent: DIARYLTHIOHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 1119
Patent: Use of diarylhydantoin compounds for treating specific cancers
Estimated Expiration: ⤷ Sign Up
Patent: 6260
Patent: DIARYLTHIOHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 0368
Patent: Diarylhydantoin compounds
Estimated Expiration: ⤷ Sign Up
Patent: 0355
Patent: Diarylhydantoin compounds
Estimated Expiration: ⤷ Sign Up
Patent: 1414
Patent: Diarylhydantoin compounds
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 9997
Estimated Expiration: ⤷ Sign Up
Patent: 1071
Estimated Expiration: ⤷ Sign Up
Patent: 2490
Estimated Expiration: ⤷ Sign Up
Patent: 17019
Estimated Expiration: ⤷ Sign Up
Patent: 076401
Estimated Expiration: ⤷ Sign Up
Patent: 084480
Estimated Expiration: ⤷ Sign Up
Patent: 161996
Patent: Diarylhydantoinforbindelse og anvendelse derav
Estimated Expiration: ⤷ Sign Up
Patent: 170919
Patent: Diaryltiohydantoinforbindelser
Estimated Expiration: ⤷ Sign Up
Patent: 180225
Patent: Diarylhydantoinforbindelser
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 93196
Estimated Expiration: ⤷ Sign Up
Patent: 44085
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 93196
Estimated Expiration: ⤷ Sign Up
Patent: 44085
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 48096
Patent: ДИАРИЛГИДАНТОИНЫ (DIARYLHYDANTOINS)
Estimated Expiration: ⤷ Sign Up
Patent: 49993
Patent: ДИАРИЛТИОГИДАНТОИНОВЫЕ СОЕДИНЕНИЯ (DIARYLTHIOHYDATOIC COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 38833
Patent: ДИАРИЛГИДАНТОИНЫ (DIARYL HYDANTOINS)
Estimated Expiration: ⤷ Sign Up
Patent: 68972
Patent: ДИАРИЛ-СПИРОГИДАНТОИНОВЫЕ СОЕДИНЕНИЯ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРПРОЛИФЕРАТИВНОГО НАРУШЕНИЯ (DIARYL-SPIROHYDANTOIC COMPOUNDS USEFUL IN HYPERPOLIFERATIVE DISORDER TREATMENT)
Estimated Expiration: ⤷ Sign Up
Patent: 07146462
Patent: ДИАРИЛГИДАНТОИНЫ
Estimated Expiration: ⤷ Sign Up
Patent: 08142728
Patent: ДИАРИЛТИОГИДАНТОИНОВЫЕ СОЕДИНЕНИЯ
Estimated Expiration: ⤷ Sign Up
Patent: 12101095
Patent: ДИАРИЛ-СПИРОГИДАНТОИНОВЫЕ СОЕДИНЕНИЯ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРПРОЛИФЕРАТИВНОГО НАРУШЕНИЯ (DIARYL-SPIROHYDANTOIC COMPOUNDS USEFUL IN HYPERPOLIFERATIVE DISORDER TREATMENT)
Estimated Expiration: ⤷ Sign Up
Patent: 17142159
Patent: ДИАРИЛГИДАНТОИНЫ
Estimated Expiration: ⤷ Sign Up
Patent: 18135606
Patent: ДИАРИЛТИОГИДАНТОИНОВЫЕ СОЕДИНЕНИЯ
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 274
Patent: JEDINJENJE DIARILHIDANTOINA (DIARZLHZDANTOIN COMPOUND)
Estimated Expiration: ⤷ Sign Up
Patent: 967
Patent: DIARIL HIDANTOIN JEDINJENJA KAO ANTAGONISTI RECEPTORA ANDROGENA ZA LEČENJE RAKA (DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 0809
Patent: DIARYLTHIOHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 201408699T
Patent: DIARYLTHIOHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 201703816S
Patent: DIARYLHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 93196
Estimated Expiration: ⤷ Sign Up
Patent: 44085
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0710870
Patent: DIARYLHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 0809098
Patent: DIARYLTHIOHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 1201793
Patent: DIARYLHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1169832
Estimated Expiration: ⤷ Sign Up
Patent: 1332889
Estimated Expiration: ⤷ Sign Up
Patent: 1332924
Estimated Expiration: ⤷ Sign Up
Patent: 1431407
Estimated Expiration: ⤷ Sign Up
Patent: 1456722
Estimated Expiration: ⤷ Sign Up
Patent: 1515335
Estimated Expiration: ⤷ Sign Up
Patent: 1519705
Estimated Expiration: ⤷ Sign Up
Patent: 1579701
Estimated Expiration: ⤷ Sign Up
Patent: 1600230
Estimated Expiration: ⤷ Sign Up
Patent: 1782236
Estimated Expiration: ⤷ Sign Up
Patent: 2020721
Estimated Expiration: ⤷ Sign Up
Patent: 2324567
Estimated Expiration: ⤷ Sign Up
Patent: 2481886
Estimated Expiration: ⤷ Sign Up
Patent: 080014039
Patent: DIARYLHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 090009215
Patent: DIARYLTHIOHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 110041580
Patent: DIARYLHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 120102140
Patent: DIARYLHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 120102147
Patent: DIARYLTHIOHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 130060369
Patent: DIARYLHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 140041831
Patent: DIARYLHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 140141676
Patent: DIARYLHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 150008506
Patent: DIARYLTHIOHYDANTOIN COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Patent: 150086567
Patent: 디아릴히단토인 화합물 (DIARYLHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 160027254
Patent: 디아릴티오히단토인 화합물 (DIARYLTHIOHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 170107585
Patent: 디아릴히단토인 화합물 (DIARYLHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 190104244
Patent: 디아릴히단토인 화합물 (DIARYLHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 210136161
Patent: 디아릴히단토인 화합물 (DIARYLHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 230003445
Patent: 디아릴히단토인 화합물 (DIARYLHYDANTOIN COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 78778
Estimated Expiration: ⤷ Sign Up
Patent: 35179
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering xtandi around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Poland | 3725778 | ⤷ Sign Up | |
| Japan | 2013136642 | DIARYLTHIOHYDANTOIN COMPOUNDS | ⤷ Sign Up |
| Mexico | 346924 | COMPUESTOS DE DIARILHIDANTOINA. (DIARYLHYDANTOIN COMPOUNDS.) | ⤷ Sign Up |
| South Africa | 201501847 | FORMULATIONS OF ENZALUTAMIDE | ⤷ Sign Up |
| European Patent Office | 4324527 | FORMULATIONS D'ENZALUTAMIDE (FORMULATIONS OF ENZALUTAMIDE) | ⤷ Sign Up |
| New Zealand | 564223 | Diarylhydantoin compounds for treating hormone refractory prostate cancer | ⤷ Sign Up |
| South Korea | 20190104244 | 디아릴히단토인 화합물 (DIARYLHYDANTOIN COMPOUNDS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for xtandi
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1893196 | 92338 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: ENZALUTAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES (XTANDI); FIRST REGISTRATION DATE: 20130625 |
| 1893196 | PA2013029,C1893196 | Lithuania | ⤷ Sign Up | PRODUCT NAME: ENZALUTAMIDUM; REGISTRATION NO/DATE: EU/1/13/846 20130625 |
| 1893196 | 2013C/074 | Belgium | ⤷ Sign Up | PRODUCT NAME: ENZALUTAMIDE (ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/13/846 20130625 |
| 1893196 | SPC/GB13/079 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ENZLUTAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/13/846 20130625 |
| 1893196 | C20130036 00106 | Estonia | ⤷ Sign Up | PRODUCT NAME: ENSALUTAMIID;REG NO/DATE: K(2013)4019 (LOPLIK) 25.06.2013 |
| 1893196 | 1390060-0 | Sweden | ⤷ Sign Up | PRODUCT NAME: ENZALUTAMID OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV; REG. NO/DATE: EU/1/13/846 20130621 |
| 1893196 | 13C0071 | France | ⤷ Sign Up | PRODUCT NAME: ENZALUTAMIDE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/846 20130625 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
